NeuroThera Labs received a Japanese patent for a novel analgesic combination aimed at enhancing treatment efficacy and safety.
Quiver AI Summary
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs Inc., has received a patent from the Japanese Patent Office for its combination treatment involving 4-aminophenol derivatives and N-acylethanolamines. This patent covers compositions and methods aimed at enhancing the pain-relieving and fever-reducing effects of existing 4-aminophenol-based therapies, with the potential for lower dosages and reduced side effects. The new patent strengthens NeuroThera's intellectual property portfolio and supports its strategies to modernize pain and fever treatments. NeuroThera aims to continue advancing its therapeutic innovations globally, focusing on providing effective and accessible treatments for central nervous system disorders.
Potential Positives
- NeuroThera Labs Inc. received a significant patent from the Japanese Patent Office, which enhances its intellectual property portfolio and reinforces its combination-therapy platforms.
- The newly granted patent may allow for lower effective dosing and reduced side effects for 4-aminophenol-based therapies, representing a potential advancement in pain and fever treatment.
- This patent is strategically important for NeuroThera as it aims to expand its therapeutic innovations into global markets.
- The press release highlights SciSparc's focus on advancing clinical-stage pharmaceutical developments, demonstrating its commitment to delivering effective treatments to patients worldwide.
Potential Negatives
- The press release focuses on a patent granted to NeuroThera, a subsidiary, which may divert attention from SciSparc's core operations and highlight dependencies on subsidiary performance.
- Forward-looking statements include various risks and uncertainties, suggesting that actual results may significantly differ from the optimistic projections provided, raising concerns about the company’s future performance.
- The mention of potential benefits from the patented combinations may raise expectations among investors that could lead to disappointment if the anticipated results are not achieved.
FAQ
What patent did NeuroThera Labs recently obtain?
NeuroThera Labs received a Japanese patent for a combination therapy involving 4-aminophenols and N-acylethanolamines.
How does the new patent benefit NeuroThera?
The patent enhances NeuroThera's intellectual property portfolio, protecting its combination-therapy platforms aimed at improving analgesic treatments.
What disorders does SciSparc focus on treating?
SciSparc focuses on central nervous system disorders, including Tourette syndrome, Alzheimer's disease, and autism spectrum disorder.
How do the patented combinations work?
The combinations are designed to enhance the effects of 4-aminophenol derivatives, potentially enabling lower doses and reducing side effects.
What is SciSparc's mission?
SciSparc aims to develop safe, effective, and accessible treatments for patients worldwide through innovative drug therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SPRC Insider Trading Activity
$SPRC insiders have traded $SPRC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SPRC stock by insiders over the last 6 months:
- ITSCHAK SHREM sold 462 shares for an estimated $4,620
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SPRC Hedge Fund Activity
We have seen 1 institutional investors add shares of $SPRC stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 22,542 shares (-87.8%) from their portfolio in Q1 2026, for an estimated $82,503
- VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC removed 20,224 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $74,019
- XTX TOPCO LTD removed 10,331 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $37,811
- STRATEGIC INVESTMENT SOLUTIONS, INC. /IL removed 133 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $734
- SBI SECURITIES CO., LTD. added 11 shares (+1100.0%) to their portfolio in Q2 2026, for an estimated $60
- ARAX ADVISORY PARTNERS removed 6 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $21
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced that the Japanese Patent Office has granted the company a patent for NeuroThera’s pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.”
The newly granted Japanese patent covers pharmaceutical compositions and methods comprising proprietary combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines. These combinations are designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies. NeuroThera believes this synergistic approach may potentially enable lower effective dosing while helping to mitigate dose‑related side‑effect concerns associated with established treatments.
This patent further strengthens NeuroThera’s expanding intellectual property portfolio reinforcing protection for its combination-therapy platforms designed to optimize and modernize standard treatments for pain, fever, and related conditions.
The addition of Japanese patent coverage marks an important strategic milestone as NeuroThera advances its next‑generation therapeutic innovations across global markets.
NeuroThera continues to advance its therapeutic platforms with the goal of delivering safe, effective, and accessible treatments to patients worldwide.
About SciSparc Ltd. (Nasdaq: SPRC):
The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
About NeuroThera Labs Inc.
NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits of the patented combinations, including their potential to enhance the effects of 4-aminophenol derivatives, potentially enable lower effective doses and address dose-related side effects, as well as the potential for NeuroThera’s proprietary combination platforms to improve established therapies for pain, fever and related conditions and NeuroThera’s advancement of its next‑generation therapeutic innovations across global markets and its goal of delivering safe, effective, and accessible treatments to patients worldwide. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
[email protected]
Tel: +972-3-6167055
